ML385 shows a specific antitumor effect for NRF2-addicted NSCLC with KEAP1 mutation both in vitro and in vivo [122,123], indicating that ML385 is another important drug candidate for the treatment of NRF2-addicted ESCC. Here, KEAP1 is linked to esophageal squamous cell carcinoma.